Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Relatlimab + Bevacizumab in Advanced/Metastatic Hepatocellular Carcinoma
NCT05337137Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2022
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 15
01
Overview
A Phase 2 trial of relatlimab in hepatocellular carcinoma (HCC), sponsored by Bristol Myers Squibb. Started May 2022; status: completed.
02
Drugs
relatlimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05337137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05337137.